Born in 1948 in Vallemosso (VC), Federico Caligaris Cappio has dedicated his life to the study and treatment of cancer. He earned a Medical Degree in 1973 from the University of Turin (Italy) and specialized in Internal Medicine and in Hematology. After a senior lectureship in immunology at the Royal Free Hospital School of Medicine in London (UK), he moved up through the ranks at the University of Turin, from Assistant Professor to Full Professor of Internal Medicine and Clinical Immunology, a position he held until 2002. From 2003 to 2015 he was Professor of Internal Medicine and Head of the Division of Internal Medicine at the University Vita-Salute San Raffaele (Milan, Italy), where he also served as Scientific Director in 2007 and later as Chairman of the Department of Oncology and of the Research Division of Molecular Oncology. He was a member of the scientific advisory board of AIRC for 7 years and has been appointed Scientific Director of AIRC in 2016.
Prof. Caligaris Cappio has had a long and distinguished career as physician scientist, focusing his clinical and research activities on lymphoid malignancies and contributing to the identification of the role of microenvironment in the accumulation of malignant cells in chronic lymphocytic leukemia and multiple myeloma. He has published over 230 peer-reviewed papers, was an invited speaker to several international scientific meetings and was awarded an honorary degree by the University of Uppsala in 2008. He has served as advisor, chairman and/or visiting professor for many prestigious societies, funding agencies and research centers worldwide, including the Multiple Myeloma Research Foundation, the Helmholtz-Alliance on Immunotherapy of Cancer, the Leukemia department of the MD Anderson Cancer Center and the Max Delbruck Center for Molecular Medicine. Prof. Caligaris Cappio has been a member of the editorial board of several international scientific journals and is a member of numerous professional associations including the American Society of Hematology, the American Society of Oncology and the European Haematology Association.